The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
/in International Publications, Malignant Melanoma /von 2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-10Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model
/in International Publications, Malignant Melanoma /von 2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-91The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells
/in Hepatocellular Carcinoma, International Publications /von 2008-10-02 / Cell. Immunol. 2009;254(2):135-41Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
/in Hypernephroma, International Publications /von 2008-10-01 / J. Immunother. 2008 Oct;31(8):771-80
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution